Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Myocardial infarction heart failure and

AIRE (87) Acute MI within 3-10 days Clinical evidence of HF 2006 Ramipril, 5-mg twice a day vs. placebo 27% Reduction of overall mortality significant reduction of severe heart failure, myocardial infarction, and stroke... [Pg.452]

Lisinopril is a non-sulfhydryl ACE inhibitor. It has been used in patients with hypertension, heart failure, myocardial infarction, and diabetic nephropathy. [Pg.2071]

Nitroglycerin remains the dmg of choice for treatment of angina pectoris. It has also been found useful for the treatment of congestive heart failure, myocardial infarction, peripheral vascular disease, such as Raynaud s disease, and mitral insufficiency, although the benefits of nitroglycerin in mitral insufficiency have been questioned. [Pg.125]

Corticosteroids should be used cautiously in the presence of congestive heart failure, myocardial infarction, hypertension, diabetes mellitus, epilepsy, glaucoma, hepatic disorders, osteoporosis, peptic ulceration, and renal impairment. Children are more susceptible to these adverse effects. To avoid cardiovascular collapse, steroids must be given slowly by intravenous injection. Large doses produce Cushing s syndrome (with moon face and sometimes hirsutism). [Pg.286]

Hypertension is defined as a sustained diastolic blood pressure greater than 90 mm Hg accompanied by an elevated systolic blood pressure (>140 mm Hg). Hypertension results from increased peripheral vascular smooth muscle tone, which leads to increased arteriolar resistance and reduced capacitance of the venous system. Elevated blood pressure is an extremely common disorder, affecting approximately 15% of the population of the United States (60 million people). Although many of these individuals have no symptoms, chronic hypertension—either systolic or diastolic—can lead to congestive heart failure, myocardial infarction, renal damage, and cerebrovascular accidents. The incidence of morbidity and mortality significantly decreases when hypertension is diagnosed early and is properly treated. [Pg.190]

Although betaxolol generally elicits less systemic beta-blockade than do noncardioselective agents, it does cause undesirable systemic effects in some patients. Reported adverse experiences include congestive heart failure, myocardial infarction, respiratory difficulties strongly suggestive of obstructive airway disease, weakness with severe sinus bradycardia, and wheezing with objective reduction in pulmonary function. [Pg.152]

Oxidative stress is defined as an imbalance between the systemic manifestation of reactive oxygen species (ROS) and reactive nitrogen species (RNS) and a biological system s ability to readily detoxify the reactive intermediates (Sies, 2015). It results in cellular damage linked to the atherosclerosis, hypertension, heart failure, myocardial infarction, malignancy, and neurodegenerative diseases such as Parkinson s disease, Alzheimer s disease, and ALS (Figure 3.8). [Pg.146]

It is well accepted that hypertension is a multifactorial disease. Only about 10% of the hypertensive patients have secondary hypertension for which causes, ie, partial coarctation of the renal artery, pheochromacytoma, aldosteronism, hormonal imbalances, etc, are known. The hallmark of hypertension is an abnormally elevated total peripheral resistance. In most patients hypertension produces no serious symptoms particularly in the early phase of the disease. This is why hypertension is called a silent killer. However, prolonged suffering of high arterial blood pressure leads to end organ damage, causing stroke, myocardial infarction, and heart failure, etc. Adequate treatment of hypertension has been proven to decrease the incidence of cardiovascular morbidity and mortaUty and therefore prolong life (176—183). [Pg.132]

Other contraindications for die anticholinergics include tachyarrhythmias, myocardial infarction, and congestive heart failure (unless bradycardia is present). [Pg.230]

Suggested Alternatives for Differential Diagnosis Acute respiratory distress syndrome, plague, congestive heart failure and pulmonary edema, HIV infection and AIDS, pneumonia, shock, phosgene, influenza, tularemia, phosphine toxicity, anthrax, silent myocardial infarction, and salicylate toxicity with pulmonary edema. [Pg.578]

Excessive doses of thyroid hormone may lead to heart failure, angina pectoris, and myocardial infarction. Allergic or idiosyncratic reactions can occur with the natural animal-derived products such as desiccated thyroid and thyroglobulin, but they are extremely rare with the synthetic products used today. Excess exogenous thyroid hormone may reduce bone density and increase the risk of fracture. [Pg.250]

Angina, arrhythmias, congestive heart failure, ischemic heart disease, myocardial infarction Endocrine and metabolic... [Pg.752]

Solomon SD, Zelenkofske S, McMurray JJ, et al. Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. NEnglJMed. Jun 23 2005 352(25) 2581-2588. [Pg.47]

Atrial fibrillation is commonly associated with heart failure, and the prevalence of atrial fibrillation is related to the severity of heart failure, with less than 5% affected with very mild heart failure to nearly 50% affected with advanced heart failure [66]. Heart failure and atrial fibrillation are both common cardiovascular disorders and share the same demographic risk factors, including age, history of hypertension, prior myocardial infarction, and valvular heart disease [67, 68]. Further, the incidence of heart failure increases dramatically after the diagnosis of atrial fibrillation [69]. Progression of LV dysfunction can clearly be associated with rapid ventricular rates [70-76]. Conversely, conversion to normal sinus rhythm or control of ventricular response in atrial fibrillation can improve LV function [71-74, 77]. Accordingly, rate control becomes very important in patients with heart failure and dilated cardiomyopathy, and likely even more so when ischemia from rapid rates complicate the patient s course. [Pg.53]

Prevention of heart failure through identification and management of risk factors in the preclinical phase of the disease is a priority. The concept of primary prevention has significant impact on the development of heart failure. It is estimated that the risk factors of hypertension, myocardial infarction, and diabetes contribute to 80% of the heart failure diagnosed in the United States [21]. More... [Pg.132]

Highly recommended are jS-blockers for those who have a prior MI event. They showed a significant effect on death. Recent studies suggest that patients who have coronary artery disease without acute myocardial infarction and/or congestive heart failure have approximately the same protective benefit against death. [Pg.588]

More recently, several large-scale clinical trials have been performed in patients with myocardial infarction and/or congestive heart failure. Some of the trials have confirmed a preventive effect on... [Pg.603]

Cardiovascular safety. Both drug types promote salt retention, can exacerbate heart failure and tend to raise blood pressure. COX-2 selective drugs also appear to raise the risks of thrombotic events, notably stroke and myocardial infarction, and recent evidence suggests that non-selective NSAIDs also raise these risks, though it is unclear whether to the same degree. For both drug types, dose and duration of treatment appear to affect risk. [Pg.623]

Captopril, as well as other ACE inhibitors, is indicated in the treatment of hypertension, congestive heart failure, left ventricular dysfunction after a myocardial infarction, and diabetic nephropathy. In the treatment of essential hypertension, captopril is considered first-choice therapy, either alone or in combination with a thiazide diuretic. Decreases in blood pressure are primarily attributed to decreased total peripheral resistance or afterload. An advantage of combining captopril therapy with a conventional thiazide diuretic is that the thiazide-induced hypokalemia is minimized in the presence of ACE inhibition, since there is a marked decrease in angiotensin Il-induced aldosterone release. [Pg.212]

Propranolol was the first blocker shown to be effective in hypertension and ischemic heart disease. Propranolol has now been largely replaced by cardioselective blockers such as metoprolol and atenolol. All B-adrenoceptor-blocking agents are useful for lowering blood pressure in mild to moderate hypertension. In severe hypertension, blockers are especially useful in preventing the reflex tachycardia that often results from treatment with direct vasodilators. Beta blockers have been shown to reduce mortality after a myocardial infarction and some also reduce mortality in patients with heart failure they are particularly advantageous for treating hypertension in patients with these conditions (see Chapter 13). [Pg.231]

ACE inhibitors have a particularly useful role in treating patients with chronic kidney disease because they diminish proteinuria and stabilize renal function (even in the absence of lowering of blood pressure). This effect is particularly valuable in diabetes, and these drugs are now recommended in diabetes even in the absence of hypertension. These benefits probably result from improved intrarenal hemodynamics, with decreased glomerular efferent arteriolar resistance and a resulting reduction of intraglomerular capillary pressure. ACE inhibitors have also proved to be extremely useful in the treatment of heart failure, and after myocardial infarction, and there is recent evidence that ACE inhibitors reduce the incidence of diabetes in patients with high cardiovascular risk (see Chapter 13). [Pg.240]

Measurements of arterial pressure, cardiac output, stroke work index, and pulmonary capillary wedge pressure are particularly useful in patients with acute myocardial infarction and acute heart failure. Such patients can be usefully characterized on the basis of three hemodynamic measurements arterial pressure, left ventricular filling pressure, and cardiac index. One such classification and therapies that have proved most effective are set forth in Table 13-4. When filling pressure is greater than 15 mm Hg and stroke work index is less than 20 g-m/m2, the mortality rate is high. Intermediate levels of these two variables imply a much better prognosis. [Pg.313]

An important class of orally active ACE inhibitors, directed against the active site of ACE, is now extensively used. Captopril and enalapril are examples of the many potent ACE inhibitors that are available. These drugs differ in their structure and pharmacokinetics, but in clinical use, they are interchangeable. ACE inhibitors decrease systemic vascular resistance without increasing heart rate, and they promote natriuresis. As described in Chapters 11 and 13, they are effective in the treatment of hypertension, decrease morbidity and mortality in heart failure and left ventricular dysfunction after myocardial infarction, and delay the progression of diabetic nephropathy. [Pg.378]


See other pages where Myocardial infarction heart failure and is mentioned: [Pg.99]    [Pg.212]    [Pg.5152]    [Pg.5151]    [Pg.129]    [Pg.654]    [Pg.99]    [Pg.212]    [Pg.5152]    [Pg.5151]    [Pg.129]    [Pg.654]    [Pg.325]    [Pg.393]    [Pg.3665]    [Pg.46]    [Pg.49]    [Pg.275]    [Pg.1068]    [Pg.519]    [Pg.10]    [Pg.22]    [Pg.362]    [Pg.33]    [Pg.315]    [Pg.153]    [Pg.212]    [Pg.415]    [Pg.37]    [Pg.249]    [Pg.241]    [Pg.63]    [Pg.250]   
See also in sourсe #XX -- [ Pg.34 , Pg.34 , Pg.45 ]

See also in sourсe #XX -- [ Pg.220 , Pg.220 , Pg.294 ]




SEARCH



Heart Myocardial infarction

Heart and

Heart failure and

Heart infarct

Infarct

Infarct, myocardial

Infarction

Myocardial infarction

Myocardial infarction and

© 2024 chempedia.info